Effect of Immunoglobulin Therapy on the Rate of Infections in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation and or Treated with Immunomodulatory Agents

Effect of Immunoglobulin Therapy on the Rate of Infections in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation and or Treated with Immunomodulatory Agents

Show other versions (1)

<p class="MsoNormal" style="margin: 0cm 0cm 0pt;"><span style="font-size: 11pt; color: windowtext; line-height: 200%; font-family: " lang="EN-US">There are few data available regarding the prevalence of infection in multiple myeloma...

Full description

Saved in:

Bibliographic Details
Main Authors:	Gerald Bates, Burns Denise, Amanda Cox, Matthias Maiwald, Alhossain A. Khalafallah, Terry Hannan, David Seaton, Bernadene Fernandopulle, Terry Brain
Format:	Article
Language:	English
Published:	PAGEPress Publications 2010-02-01
Series:	Mediterranean Journal of Hematology and Infectious Diseases
Subjects:	Multiple myeloma, autologous stem cell transplantation, immunomodulatory drugs, intravenous immunoglobulin, bacterial infection, viral infection.
Online Access:	http://www.mjhid.org/article/view/5590
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	<p class="MsoNormal" style="margin: 0cm 0cm 0pt;"><span style="font-size: 11pt; color: windowtext; line-height: 200%; font-family: " lang="EN-US">There are few data available regarding the prevalence of infection in multiple myeloma (MM) patients in conjunction with newer generations of immunomodulatory drugs (thalidomide, bortezomib, lenalidomide) or post autologous stem cell transplantation.<span style="mso-spacerun: yes;"> </span>We retrospectively analyzed 47 patients with MM from March 2006 to June 2009 at our institution. All patients received thalidomide and steroid therapy for at least 6 months. Nine patients received bortezomib and 11 lenalidomide subsequently to thalidomide, because of disease progression and 22 patients underwent autologous stem cell transplantation.<strong style="mso-bidi-font-weight: normal;"><span style="mso-spacerun: yes;"> </span></strong><span style="mso-spacerun: yes;"> </span>The median age was 64 years (range 37-86), with a female–to-male ratio of 18:29. The median residual-serum IgG-level at time of infection was 3.2 g/L, IgA 0.3 g/L and IgM 0.2 g/L. Most patients suffered from recurrent moderate to severe infections. All patients except 3 received intravenous immunoglobulin (IVIG) therapy with a significant decline of the rate of infection thereafter. Our analysis shows that IVIG appears to be an effective strategy to prevent infection in MM patients. Further studies to confirm these findings are warranted. </span></p>
ISSN:	2035-3006